COSCIENS Biopharma (CSCI) Stock Price, News & Analysis

Company Overview

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $3.30 to $3.45
• 50-Day Range: $3.05 to $3.82
• 52-Week Range: $1.96 to $6.77
• Volume: 640 shs
• Average Volume: 11,401 shs
• Market Capitalization: $10.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CSCI Stock Analysis - Frequently Asked Questions

How have CSCI shares performed this year?

COSCIENS Biopharma's stock was trading at $2.77 on January 1st, 2025. Since then, CSCI shares have increased by 20.2% and is now trading at $3.33.
View the best growth stocks for 2025 here.

How were COSCIENS Biopharma's earnings last quarter?

COSCIENS Biopharma Inc. (NASDAQ:CSCI) released its earnings results on Tuesday, May, 13th. The company reported ($1.16) earnings per share for the quarter. The company had revenue of $1.50 million for the quarter. COSCIENS Biopharma had a negative trailing twelve-month return on equity of 101.01% and a negative net margin of 194.50%.

How do I buy shares of COSCIENS Biopharma?

Shares of CSCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of COSCIENS Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that COSCIENS Biopharma investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/27/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CSCI
• CIK: 1113423
• Web: www.cosciensbio.com
• Phone: 49-6942-6020
• Fax: 418-948-9191
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($5.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.31 million
• Net Margins: -194.50%
• Pretax Margin: -189.00%
• Return on Equity: -101.01%
• Return on Assets: -43.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.88
• Quick Ratio: 2.54

Sales & Book Value

• Annual Sales: $9.59 million
• Price / Sales: 1.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.49 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 3,150,000
• Free Float: 3,144,000
• Market Cap: $10.49 million
• Optionable: N/A
• Beta: 0.74